Literature DB >> 23864668

Gait abnormalities and progressive myelin degeneration in a new murine model of Pelizaeus-Merzbacher disease with tandem genomic duplication.

Kristi Clark1, Lauren Sakowski, Karen Sperle, Linda Banser, Carlisle P Landel, Denise A Bessert, Robert P Skoff, Grace M Hobson.   

Abstract

Pelizaeus-Merzbacher disease (PMD) is a hypomyelinating leukodystrophy caused by mutations of the proteolipid protein 1 gene (PLP1), which is located on the X chromosome and encodes the most abundant protein of myelin in the central nervous sytem. Approximately 60% of PMD cases result from genomic duplications of a region of the X chromosome that includes the entire PLP1 gene. The duplications are typically in a head-to-tail arrangement, and they vary in size and gene content. Although rodent models with extra copies of Plp1 have been developed, none contains an actual genomic rearrangement that resembles those found in PMD patients. We used mutagenic insertion chromosome engineering resources to generate the Plp1dup mouse model by introducing an X chromosome duplication in the mouse genome that contains Plp1 and five neighboring genes that are also commonly duplicated in PMD patients. The Plp1dup mice display progressive gait abnormalities compared with wild-type littermates. The single duplication leads to increased transcript levels of Plp1 and four of the five other duplicated genes over wild-type levels in the brain beginning the second postnatal week. The Plp1dup mice also display altered transcript levels of other important myelin proteins leading to a progressive degeneration of myelin. Our results show that a single duplication of the Plp1 gene leads to a phenotype similar to the pattern seen in human PMD patients with duplications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23864668      PMCID: PMC3713721          DOI: 10.1523/JNEUROSCI.1336-13.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  36 in total

1.  Endoplasmic reticulum stress in PLP-overexpressing transgenic rats: gray matter oligodendrocytes are more vulnerable than white matter oligodendrocytes.

Authors:  Jan Bauer; Monika Bradl; Matthias Klein; Marianne Leisser; Thomas L Deckwerth; Hartmut Wekerle; Hans Lassmann
Journal:  J Neuropathol Exp Neurol       Date:  2002-01       Impact factor: 3.685

Review 2.  Distinct phenotypes associated with increasing dosage of the PLP gene: implications for CMT1A due to PMP22 gene duplication.

Authors:  T J Anderson; M Klugmann; C E Thomson; A Schneider; C Readhead; K A Nave; I R Griffiths
Journal:  Ann N Y Acad Sci       Date:  1999-09-14       Impact factor: 5.691

3.  Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet.

Authors:  Gesine Saher; Fabian Rudolphi; Kristina Corthals; Torben Ruhwedel; Karl-Friedrich Schmidt; Siegrid Löwel; Payam Dibaj; Benoit Barrette; Wiebke Möbius; Klaus-Armin Nave
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

4.  Evidence for disease penetrance relating to CNV size: Pelizaeus-Merzbacher disease and manifesting carriers with a familial 11 Mb duplication at Xq22.

Authors:  C M B Carvalho; M Bartnik; D Pehlivan; P Fang; J Shen; J R Lupski
Journal:  Clin Genet       Date:  2011-06-20       Impact factor: 4.438

5.  Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice.

Authors:  Tao Yu; Chunhong Liu; Pavel Belichenko; Steven J Clapcote; Shaomin Li; Annie Pao; Alexander Kleschevnikov; Allison R Bechard; Suhail Asrar; Rongqing Chen; Ni Fan; Zhenyu Zhou; Zhengping Jia; Chu Chen; John C Roder; Bin Liu; Antonio Baldini; William C Mobley; Y Eugene Yu
Journal:  Brain Res       Date:  2010-10-26       Impact factor: 3.252

6.  Characterization of a PLP-overexpressing transgenic rat, a model for the connatal form of Pelizaeus-Merzbacher disease.

Authors:  Joshua A Mayer; Eric C Larsen; Yoichi Kondo; Ian D Duncan
Journal:  Neurobiol Dis       Date:  2011-07-18       Impact factor: 5.996

7.  Genetic background determines phenotypic severity of the Plp rumpshaker mutation.

Authors:  K Al-Saktawi; M McLaughlin; M Klugmann; A Schneider; J A Barrie; M C McCulloch; P Montague; D Kirkham; K-A Nave; I R Griffiths
Journal:  J Neurosci Res       Date:  2003-04-01       Impact factor: 4.164

8.  Dysregulation of axonal sodium channel isoforms after adult-onset chronic demyelination.

Authors:  Matthew N Rasband; Tetsushi Kagawa; Eunice W Park; Kazuhiro Ikenaka; James S Trimmer
Journal:  J Neurosci Res       Date:  2003-08-15       Impact factor: 4.164

Review 9.  Where, when and how much: regulation of myelin proteolipid protein gene expression.

Authors:  P A Wight; A Dobretsova
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  16 in total

1.  Inducible Expression of a Truncated Form of Tau in Oligodendrocytes Elicits Gait Abnormalities and a Decrease in Myelin: Implications for Selective CNS Degenerative Diseases.

Authors:  Patrizia LoPresti
Journal:  Neurochem Res       Date:  2015-09-22       Impact factor: 3.996

Review 2.  Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease.

Authors:  M Joana Osorio; David H Rowitch; Paul Tesar; Marius Wernig; Martha S Windrem; Steven A Goldman
Journal:  Stem Cells       Date:  2016-11-23       Impact factor: 6.277

3.  Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes.

Authors:  Zachary S Nevin; Daniel C Factor; Robert T Karl; Panagiotis Douvaras; Jeremy Laukka; Martha S Windrem; Steven A Goldman; Valentina Fossati; Grace M Hobson; Paul J Tesar
Journal:  Am J Hum Genet       Date:  2017-03-30       Impact factor: 11.025

4.  The wmN1 enhancer region in intron 1 is required for expression of human PLP1.

Authors:  Hamdan Hamdan; Pankaj Patyal; Neriman T Kockara; Patricia A Wight
Journal:  Glia       Date:  2018-04-23       Impact factor: 7.452

5.  Plp1 gene duplication inhibits airway responsiveness and induces lung inflammation.

Authors:  Elena Rodriguez; Lauren Sakowski; Grace M Hobson; Milena Hirata Armani; Portia A Kreiger; Yan Zhu; Scott A Waldman; Thomas H Shaffer
Journal:  Pulm Pharmacol Ther       Date:  2014-11-04       Impact factor: 3.410

6.  Insertion of proteolipid protein into mitochondria but not DM20 regulates metabolism of cells.

Authors:  Mallika Somayajulu; Denise A Bessert; Maik Hüttemann; Jasloveleen Sohi; John Kamholz; Robert P Skoff
Journal:  Neurosci Lett       Date:  2018-05-02       Impact factor: 3.046

7.  The wmN1 Enhancer Region of the Mouse Myelin Proteolipid Protein Gene (mPlp1) is Indispensable for Expression of an mPlp1-lacZ Transgene in Both the CNS and PNS.

Authors:  Pankaj Patyal; Neriman T Kockara; Patricia A Wight
Journal:  Neurochem Res       Date:  2019-11-28       Impact factor: 3.996

8.  Novel pathologic findings in patients with Pelizaeus-Merzbacher disease.

Authors:  Jeremy J Laukka; John Kamholz; Denise Bessert; Robert P Skoff
Journal:  Neurosci Lett       Date:  2016-05-17       Impact factor: 3.046

Review 9.  Neurogenetics of Pelizaeus-Merzbacher disease.

Authors:  M Joana Osório; Steven A Goldman
Journal:  Handb Clin Neurol       Date:  2018

10.  Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression.

Authors:  Eleonora Maino; Daria Wojtal; Sonia L Evagelou; Aiman Farheen; Tatianna W Y Wong; Kyle Lindsay; Ori Scott; Samar Z Rizvi; Elzbieta Hyatt; Matthew Rok; Shagana Visuvanathan; Amanda Chiodo; Michelle Schneeweiss; Evgueni A Ivakine; Ronald D Cohn
Journal:  EMBO Mol Med       Date:  2021-03-16       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.